Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial

埃索美拉唑 医学 阿莫西林 幽门螺杆菌 内科学 克拉霉素 胃肠病学 不利影响 尿素呼气试验 随机对照试验 呼吸试验 意向治疗分析 抗生素 幽门螺杆菌感染 生物 微生物学
作者
Dan‐Ni Liu,Qiuyan Wang,Peiyuan Li,Donghan Wu,Jing Pan,Zhengyi Chen,Yanqiang Li,Xiang-Yang Han,Lan Cheng,Jing Tang,Yan Tan,Cui-Yi Mo,Weizhong Yang,Jun-Ling Han,Xiaoxi Huang
出处
期刊:Clinics and Research in Hepatology and Gastroenterology [Elsevier BV]
卷期号:47 (5): 102125-102125 被引量:6
标识
DOI:10.1016/j.clinre.2023.102125
摘要

Traditional bismuth-containing quadruple therapy, as a first-line eradication treatment for Helicobacter pylori (H. pylori), has several disadvantages, including drug side effects, low medication adherence, and high costs. Trials of high-dose dual treatment have demonstrated its advantages, which include good safety and adherence profiles. In this study, we investigated the efficacy, safety, and compliance of a high-dose dual therapy when compared with bismuth-based quadruple treatment for the initial eradication of H. pylori infection on Hainan Island, China. We randomized 846 H. pylori-infected patients into two groups. A bismuth-containing quadruple therapy group was administered the following: esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily, and colloidal bismuth pectin in suspension 150 mg three times/day for 2 weeks. A high-dose dual therapy group was administered the following: esomeprazole 20 mg four times/day and amoxicillin 1000 mg three times/day for 2 weeks. Patients were given a 13C urea breath test at 4 weeks at treatment end. Adverse effects and compliance were evaluated at follow-up visits. Eradication rates in the high-dose dual therapy group were: 90.3% (381/422, 95% confidence interval [CI]: 87.1%–92.9%) in intention-to-treat (ITT) and 93.6% (381/407, 95% CI: 90.8%–95.8%) in per-protocol (PP) analyses. Eradication rates were 87.3% in ITT (370/424, 95% CI: 83.7%–90.3%) and 91.8% in PP analyses (370/403, 95% CI: 88.7%–94.3%) for quadruple therapy, with no statistical differences (P = 0.164 in ITT and P = 0.324 in PP analyses). Adverse effects were 13.5% (55/407) in the dual group and 17.4% (70/403) in the quadruple group (P = 0.129). Compliance was 92.4% (376/407) in the dual group and 86.6% (349/403) in the quadruple group (P = 0.007). High-dose dual therapy had high eradication rates comparable with bismuth-based quadruple treatment, with no differences in adverse effects, however higher adherence rates were recorded.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
luckweb完成签到,获得积分10
1秒前
猫的毛完成签到 ,获得积分10
2秒前
nicky完成签到 ,获得积分10
3秒前
麦子完成签到 ,获得积分10
4秒前
4秒前
Wilson完成签到 ,获得积分10
5秒前
luckweb发布了新的文献求助10
5秒前
5秒前
9秒前
12秒前
传奇3应助wujiwuhui采纳,获得10
14秒前
开心寄松完成签到,获得积分10
16秒前
北宫完成签到 ,获得积分10
16秒前
wansida完成签到,获得积分10
20秒前
QXS完成签到 ,获得积分10
20秒前
21秒前
菠萝完成签到 ,获得积分10
21秒前
领导范儿应助Villanellel采纳,获得10
25秒前
wintersss完成签到,获得积分10
25秒前
尹尹发布了新的文献求助10
26秒前
量子星尘发布了新的文献求助10
28秒前
zzzzzz完成签到 ,获得积分10
32秒前
坦率的枕头完成签到,获得积分10
32秒前
XS_QI完成签到 ,获得积分10
32秒前
与共发布了新的文献求助10
35秒前
苑阿宇完成签到 ,获得积分10
35秒前
yck1027完成签到,获得积分10
36秒前
fatcat完成签到,获得积分10
36秒前
斯文败类应助Camus采纳,获得10
37秒前
39秒前
Tammy完成签到 ,获得积分10
39秒前
Herisland完成签到 ,获得积分10
41秒前
lulalula完成签到,获得积分10
42秒前
NEO完成签到 ,获得积分10
44秒前
zcydbttj2011完成签到 ,获得积分10
46秒前
温暖的小鸭子完成签到,获得积分10
48秒前
52秒前
王泽厚发布了新的文献求助20
53秒前
雪花发布了新的文献求助10
55秒前
周全完成签到 ,获得积分10
59秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022